Protrieve 鞘在 22 例静脉血栓清除术中血栓栓塞防护的可行性
单中心可行性研究纳入 22 例深静脉血栓清除术患者,使用 Protrieve 鞘进行栓塞防护。
要点
- 临床成功率为 95.5%,无器械相关不良事件
- 45.5% 患者需支架重建,常见症状为肢体肿胀(86.4%)
核心结论
- 在大口径静脉机械血栓清除术中使用 Protrieve 鞘可获得良好的技术和临床结果,无器械相关不良事件或临床显著血栓栓塞事件。
主要发现
- 最常见症状为肢体肿胀(19 例,86.4%)。
- 9 例(40.9%)为恶性病因,13 例(59.1%)为良性病因;9 例恶性肿瘤中 5 例组织学分析确定为肿瘤血栓(55.5%)。
- 受阻静脉段包括下腔静脉和下肢(13 例,59.1%)、单纯下肢(4 例,18.2%)、单纯下腔静脉(3 例,13.6%)、胸部中心静脉和上腔静脉(1 例,4.5%)、单纯胸部中心静脉(1 例,4.5%)。
- 无即刻器械相关不良事件,包括 Protrieve 鞘网篮部署失败、出血或临床显著栓塞事件。
关键数值与推荐
- 技术成功定义为成功将 Protrieve 鞘漏斗部署在血栓清除部位近端。
- 临床成功定义为静脉闭塞症状改善且无手术相关静脉血栓栓塞。
- Protrieve 鞘入路部位包括右颈内静脉(20 例,90.9%)用于下腔静脉和下肢梗阻,右股总静脉(2 例,9.1%)用于胸部中心静脉和上腔静脉梗阻。
- Protrieve 鞘漏斗部署位置包括肝内下腔静脉 18 例(81.8%)、肾上下腔静脉 2 例(9.1%)、上腔静脉心房交界处 2 例(9.1%)。
- 10 例(45.5%)患者在血栓清除后需要支架重建。
临床怎么用
- 对于大血管静脉血栓栓塞性疾病,可考虑在机械血栓清除术中使用 Protrieve 鞘进行栓塞防护。
- 术后随访包括 1、3、6、12 个月的双侧下肢双功超声和腹部盆腔 CT 静脉造影。
局限性
- 样本量小(22 例),为单中心可行性研究。
- 需要与标准技术进行比较研究以更好地量化该器械的潜在获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Protrieve Sheath (Inari Medical; Irvine, CA) is a thromboembolic protection device for venous thrombectomy. An extended feasibility study was conducted for device use in deep vein thrombectomy and inferior vena cava (IVC) filter removal. METHODS: Twenty-two patients, including 12 (55.5%) females and 10 (45.5%) males (mean age 55.8 ± 13.9 years, range 28-81 years), underwent deep venous thrombectomy using the Protrieve Sheath for embolic protection between November 2022 and July 2024 (21 months). The Food and Drug Administration-approved modified sheath contains an extendable nitinol mesh for large vessel thrombectomy outside the heart including the extremities, ileocaval, IVC, and superior vena cava. The following demographic information was recorded: presenting symptoms, procedural indications, obstructed venous segments, Protrieve Sheath access and deployment sites, thrombectomy devices utilized (ClotTriever, Inthrill, Lightning Flash 16, RevCore), need for stent reconstruction, technical success, clinical success, procedural complications related to device access and deployment, clinically significant embolic events, procedure-related injury, hematoma, mortality, death, and removed thrombi histological analyses. Technical success was defined as successfully deploying the Protrieve Sheath funnel proximal to the thrombectomy site. Clinical success was defined as improvement in presenting venous occlusive symptoms without procedure-related venous thromboembolism. All patients were followed with bilateral lower extremity duplex ultrasounds and computed tomography venogram abdomen and pelvis at 1 month, 3 months, 6 months, and 12 months. Patients were seen in clinic at 1 month, 3 months, 6 months, and 12 months. RESULTS: The most common presenting symptom was extremity swelling (n = 19; 86.4%). Nine (40.9%) patients had malignant, and 13 (59.1%) had benign etiologies of venous obstruction. Of the 9 patients with malignancy, 5 were determined to be tumor thrombus on histological analysis (n = 5, 55.5%). Obstructed venous segments included the IVC and lower extremity (n = 13; 59.1%), isolated lower extremity (n = 4; 18.2%), isolated IVC (n = 3; 13.6%), thoracic central veins and superior vena cava (n = 1; 4.5%), and isolated thoracic central vein (n = 1; 4.5%). The Protrieve Sheath access sites included the right internal jugular vein (n = 20; 90.9%) for IVC and lower extremity obstructions and the right common femoral vein (n = 2; 9.1%) for thoracic central vein and superior vena cava obstructions. The Protrieve Sheath funnel deployment locations included intrahepatic IVC in 18 patients (n = 13; 81.8%), suprarenal IVC in 2 (n = 2; 9.1%), and superior cavoatrial junction in 2 (n = 2; 9.1%). Ten (45.5%) patients required stent reconstruction following thrombectomy. Technical success was achieved in all patients. Clinical success was achieved in 21 (95.5%) patients. No immediate device-related adverse events including mesh maldeployment of the Protrieve Sheath, hemorrhage, or clinically significant embolic events occurred. CONCLUSION: Use of the Protrieve Sheath during large-bore venous mechanical thrombectomy resulted in favorable technical and clinical outcomes without device-related adverse events or clinically significant thromboembolic events. These results suggest further implementation and investigation of the devices use in complex large vessel thromboembolic disease. Comparative studies to standard technique can better quantify the potential benefits of this device.
引用
- Campbell W, Summers F, Greenberg C, et al. Feasibility of the Protrieve Sheath for Embolic Protection During Venous Thrombectomy in Twenty-two Patients. Ann Vasc Surg. 2025. PMID: 40582459. doi:10.1016/j.avsg.2025.06.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。